AG˹ٷ

STOCK TITAN

[Form 4] Amplify Energy Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for Y-mAbs Therapeutics (YMAB) discloses that director Laura Hamill received new equity awards on 30 June 2025.

  • Restricted Stock Units: 25,080 RSUs granted at no cost. The award vests in full on the earlier of 12 months after grant or immediately before the 2026 annual shareholder meeting, subject to continued service.
  • Stock Options: 33,450 options with a US$4.51 exercise price, expiring 30 June 2035. Vest in equal monthly instalments over one year and become exercisable upon vesting.
  • Post-transaction ownership: Hamill now directly holds 30,905 YMAB common shares and 33,450 vested/unvested options.

The transactions reflect routine director compensation under the 2018 Equity Incentive Plan and do not involve open-market purchases or sales.

La dichiarazione Form 4 per Y-mAbs Therapeutics (YMAB) rivela che la direttrice Laura Hamill ha ricevuto nuove assegnazioni di azioni il 30 giugno 2025.

  • Unità di Azioni Vincolate (RSU): 25.080 RSU assegnate gratuitamente. L'assegnazione matura completamente al primo verificarsi tra 12 mesi dalla concessione o immediatamente prima dell'assemblea annuale degli azionisti del 2026, subordinatamente alla continuazione del servizio.
  • Opzioni su Azioni: 33.450 opzioni con un prezzo di esercizio di 4,51 USD, in scadenza il 30 giugno 2035. Maturano in rate mensili uguali nell'arco di un anno e diventano esercitabili al momento della maturazione.
  • Possesso post-transazione: Hamill detiene ora direttamente 30.905 azioni ordinarie YMAB e 33.450 opzioni maturate/non maturate.

Le transazioni riflettono la normale remunerazione dei direttori secondo il Piano Incentivi Azionari 2018 e non coinvolgono acquisti o vendite sul mercato aperto.

La presentación del Formulario 4 para Y-mAbs Therapeutics (YMAB) revela que la directora Laura Hamill recibió nuevas concesiones de acciones el 30 de junio de 2025.

  • Unidades de Acciones Restringidas (RSU): 25,080 RSU otorgadas sin costo. La concesión se completa en su totalidad al cumplirse 12 meses desde la concesión o justo antes de la reunión anual de accionistas de 2026, sujeto a la continuidad del servicio.
  • Opciones sobre Acciones: 33,450 opciones con un precio de ejercicio de 4,51 USD, que expiran el 30 de junio de 2035. Se consolidan en cuotas mensuales iguales durante un año y se vuelven ejercitables al consolidarse.
  • Propiedad post-transacción: Hamill ahora posee directamente 30,905 acciones ordinarias de YMAB y 33,450 opciones ejercitadas/no ejercitadas.

Las transacciones reflejan una compensación rutinaria para directores bajo el Plan de Incentivos de Capital 2018 y no implican compras o ventas en el mercado abierto.

Y-mAbs Therapeutics(YMAB)� Form 4 제출� 따르� 이사� Laura Hamill� 2025� 6� 30일에 새로� 주식 보상� 받았습니�.

  • 제한 주식 단위(RSUs): 25,080 RSU가 무상으로 부여되었습니다. � 보상은 부� � 12개월� 경과하거� 2026� 연례 주주총회 직전� 전액 베스팅되�, 계속 근무 조건� 적용됩니�.
  • 주식 옵션: 행사 가격이 4.51달러� 33,450개의 옵션� 2035� 6� 30일에 만료됩니�. 1� 동안 매월 동일� 비율� 베스팅되�, 베스� 시점� 행사� � 있습니다.
  • 거래 � 보유 현황: Hamill은 현재 YMAB 보통� 30,905주와 베스팅된/베스팅되지 않은 옵션 33,450주를 직접 보유하고 있습니다.

� 거래� 2018� 주식 인센티브 계획� 따른 정기적인 이사 보상이며, 공개 시장에서� 매매� 포함되지 않습니다.

Le dépôt du Formulaire 4 pour Y-mAbs Therapeutics (YMAB) révèle que la directrice Laura Hamill a reçu de nouvelles attributions d'actions le 30 juin 2025.

  • Unités d'Actions Restreintes (RSU) : 25 080 RSU attribuées gratuitement. L'attribution est entièrement acquise au plus tôt 12 mois après l'octroi ou juste avant l'assemblée générale annuelle de 2026, sous réserve de la poursuite du service.
  • Options d'Achat d'Actions : 33 450 options avec un prix d'exercice de 4,51 USD, expirant le 30 juin 2035. Elles acquièrent droit par versements mensuels égaux sur un an et deviennent exerçables dès acquisition.
  • Possession après la transaction : Hamill détient désormais directement 30 905 actions ordinaires YMAB et 33 450 options acquises/non acquises.

Ces transactions reflètent la rémunération habituelle des administrateurs selon le Plan d'Incitation en Actions 2018 et n'impliquent pas d'achats ou ventes sur le marché ouvert.

Formular 4 Einreichung für Y-mAbs Therapeutics (YMAB) zeigt, dass Direktorin Laura Hamill am 30. Juni 2025 neue Aktienzuteilungen erhalten hat.

  • Restricted Stock Units (RSUs): 25.080 RSUs wurden kostenlos gewährt. Die Zuteilung wird entweder 12 Monate nach Gewährung oder unmittelbar vor der Hauptversammlung 2026 vollständig fällig, vorbehaltlich der fortgesetzten Dienstzeit.
  • Aktienoptionen: 33.450 Optionen mit einem Ausübungspreis von 4,51 USD, die am 30. Juni 2035 verfallen. Sie werden über ein Jahr in gleichen monatlichen Raten fällig und sind bei Fälligkeit ausübbar.
  • Besitz nach der Transaktion: Hamill hält nun direkt 30.905 YMAB Stammaktien und 33.450 ausgeübte/nicht ausgeübte Optionen.

Die Transaktionen spiegeln die routinemäßige Vergütung von Direktoren gemäß dem Equity Incentive Plan 2018 wider und beinhalten keine Käufe oder Verkäufe am offenen Markt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR � Routine equity grants; negligible impact on YMAB valuation.

The filing records standard annual equity compensation for a non-executive director. No shares were bought or sold in the market; therefore, no immediate cash flow effect on the company and no strong signalling value regarding insider sentiment. Grants align the director’s incentives with shareholders but are immaterial relative to YMAB’s ~41 million shares outstanding. Overall investor impact is neutral.

La dichiarazione Form 4 per Y-mAbs Therapeutics (YMAB) rivela che la direttrice Laura Hamill ha ricevuto nuove assegnazioni di azioni il 30 giugno 2025.

  • Unità di Azioni Vincolate (RSU): 25.080 RSU assegnate gratuitamente. L'assegnazione matura completamente al primo verificarsi tra 12 mesi dalla concessione o immediatamente prima dell'assemblea annuale degli azionisti del 2026, subordinatamente alla continuazione del servizio.
  • Opzioni su Azioni: 33.450 opzioni con un prezzo di esercizio di 4,51 USD, in scadenza il 30 giugno 2035. Maturano in rate mensili uguali nell'arco di un anno e diventano esercitabili al momento della maturazione.
  • Possesso post-transazione: Hamill detiene ora direttamente 30.905 azioni ordinarie YMAB e 33.450 opzioni maturate/non maturate.

Le transazioni riflettono la normale remunerazione dei direttori secondo il Piano Incentivi Azionari 2018 e non coinvolgono acquisti o vendite sul mercato aperto.

La presentación del Formulario 4 para Y-mAbs Therapeutics (YMAB) revela que la directora Laura Hamill recibió nuevas concesiones de acciones el 30 de junio de 2025.

  • Unidades de Acciones Restringidas (RSU): 25,080 RSU otorgadas sin costo. La concesión se completa en su totalidad al cumplirse 12 meses desde la concesión o justo antes de la reunión anual de accionistas de 2026, sujeto a la continuidad del servicio.
  • Opciones sobre Acciones: 33,450 opciones con un precio de ejercicio de 4,51 USD, que expiran el 30 de junio de 2035. Se consolidan en cuotas mensuales iguales durante un año y se vuelven ejercitables al consolidarse.
  • Propiedad post-transacción: Hamill ahora posee directamente 30,905 acciones ordinarias de YMAB y 33,450 opciones ejercitadas/no ejercitadas.

Las transacciones reflejan una compensación rutinaria para directores bajo el Plan de Incentivos de Capital 2018 y no implican compras o ventas en el mercado abierto.

Y-mAbs Therapeutics(YMAB)� Form 4 제출� 따르� 이사� Laura Hamill� 2025� 6� 30일에 새로� 주식 보상� 받았습니�.

  • 제한 주식 단위(RSUs): 25,080 RSU가 무상으로 부여되었습니다. � 보상은 부� � 12개월� 경과하거� 2026� 연례 주주총회 직전� 전액 베스팅되�, 계속 근무 조건� 적용됩니�.
  • 주식 옵션: 행사 가격이 4.51달러� 33,450개의 옵션� 2035� 6� 30일에 만료됩니�. 1� 동안 매월 동일� 비율� 베스팅되�, 베스� 시점� 행사� � 있습니다.
  • 거래 � 보유 현황: Hamill은 현재 YMAB 보통� 30,905주와 베스팅된/베스팅되지 않은 옵션 33,450주를 직접 보유하고 있습니다.

� 거래� 2018� 주식 인센티브 계획� 따른 정기적인 이사 보상이며, 공개 시장에서� 매매� 포함되지 않습니다.

Le dépôt du Formulaire 4 pour Y-mAbs Therapeutics (YMAB) révèle que la directrice Laura Hamill a reçu de nouvelles attributions d'actions le 30 juin 2025.

  • Unités d'Actions Restreintes (RSU) : 25 080 RSU attribuées gratuitement. L'attribution est entièrement acquise au plus tôt 12 mois après l'octroi ou juste avant l'assemblée générale annuelle de 2026, sous réserve de la poursuite du service.
  • Options d'Achat d'Actions : 33 450 options avec un prix d'exercice de 4,51 USD, expirant le 30 juin 2035. Elles acquièrent droit par versements mensuels égaux sur un an et deviennent exerçables dès acquisition.
  • Possession après la transaction : Hamill détient désormais directement 30 905 actions ordinaires YMAB et 33 450 options acquises/non acquises.

Ces transactions reflètent la rémunération habituelle des administrateurs selon le Plan d'Incitation en Actions 2018 et n'impliquent pas d'achats ou ventes sur le marché ouvert.

Formular 4 Einreichung für Y-mAbs Therapeutics (YMAB) zeigt, dass Direktorin Laura Hamill am 30. Juni 2025 neue Aktienzuteilungen erhalten hat.

  • Restricted Stock Units (RSUs): 25.080 RSUs wurden kostenlos gewährt. Die Zuteilung wird entweder 12 Monate nach Gewährung oder unmittelbar vor der Hauptversammlung 2026 vollständig fällig, vorbehaltlich der fortgesetzten Dienstzeit.
  • Aktienoptionen: 33.450 Optionen mit einem Ausübungspreis von 4,51 USD, die am 30. Juni 2035 verfallen. Sie werden über ein Jahr in gleichen monatlichen Raten fällig und sind bei Fälligkeit ausübbar.
  • Besitz nach der Transaktion: Hamill hält nun direkt 30.905 YMAB Stammaktien und 33.450 ausgeübte/nicht ausgeübte Optionen.

Die Transaktionen spiegeln die routinemäßige Vergütung von Direktoren gemäß dem Equity Incentive Plan 2018 wider und beinhalten keine Käufe oder Verkäufe am offenen Markt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Snyder Todd R

(Last) (First) (Middle)
C/O AMPLIFY ENERGY CORP
500 DALLAS ST. SUITE 1700

(Street)
HOUSTON TX 77002

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Amplify Energy Corp. [ AMPY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.01 per share 07/01/2025 M 19,665 A (1) 128,081 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 07/01/2025 M 19,665 (2) (2) Common Stock 19,665 $0 0 D
Restricted Stock Units (3) 07/01/2025 A 36,459 (3) (3) Common Stock 36,459 $0 36,459 D
Explanation of Responses:
1. Reflects shares of common stock, par value $0.01 per share of Amplify Energy Corp. (the "Company") granted upon settlement of previously awarded restricted stock units with service-based vesting conditions ("TSUs").
2. These TSUs were granted under the Amplify Energy Corp.2024 Equity Incentive Plan, vesting on the first anniversary of the date of grant so long as the reporting person remained a member of the board of directors of the Company through the vesting date.
3. Share amount reflects an aggregate number and represents 36,459 unvested TSUs. These TSUs were granted under the Amplify Energy Corp. 2024 Equity Incentive Plan and vest on the first anniversary of the date of grant so long as the reporting person remains a member of the board of directors of the Company through the vesting date. The TSUs convert into common stock on a one-for-one basis.
/s/ Eric M. Willis, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did YMAB director Laura Hamill receive on 30 June 2025?

She was granted 25,080 RSUs and 33,450 stock options with a US$4.51 exercise price.

When do the 25,080 RSUs granted to Laura Hamill vest?

They vest in full on the earlier of one year after grant or immediately before YMAB’s 2026 annual meeting, subject to continued service.

What is the exercise window for the 33,450 options issued to Laura Hamill?

The options vest monthly over one year and are exercisable upon vesting, expiring on 30 June 2035.

How many YMAB common shares does Laura Hamill own after the reported transactions?

She directly owns 30,905 shares of YMAB common stock.

Did the Form 4 indicate any open-market purchase or sale of YMAB shares?

No. The filing only shows equity awards; there were no open-market transactions.
Amplify Energy Corp

NYSE:AMPY

AMPY Rankings

AMPY Latest News

AMPY Latest SEC Filings

AMPY Stock Data

140.37M
35.86M
9.48%
53.1%
3.28%
Oil & Gas E&P
Crude Petroleum & Natural Gas
United States
HOUSTON